JAAD International最新文献

英文中文

Telemedicine visits for new onychomycosis diagnoses result in fewer antifungal prescriptions than in-person care: A retrospective cohort study 新诊断的甲真菌病的远程医疗访问导致抗真菌处方少于现场护理：一项回顾性队列研究

IF 5.2

JAAD International

Pub Date : 2025-11-29 DOI: 10.1016/j.jdin.2025.11.019

Sonya V. Gupta BS, MA , Kevin Chen BS, MS , Christina Tang BS , C. William Pike MD , Gavin Hui MD , Jeremy R. Coyle PhD , Jasmine Rana MD, MMSc

引用次数: 0

Real-world effectiveness and safety of lebrikizumab maintenance dosing every 4 weeks starting at week 4 after 2 loading doses in Japanese patients with atopic dermatitis 在日本特应性皮炎患者中，2次负荷剂量后，从第4周开始，每4周给予lebrikizumab维持剂量的实际有效性和安全性

IF 5.2

JAAD International

Pub Date : 2025-11-28 DOI: 10.1016/j.jdin.2025.11.014

Yoshiki Okada MD, Masahiro Kamata MD, PhD, Shoya Suzuki MD, Ayu Watanabe MD, PhD, Chika Chijiwa MD, PhD, Yayoi Tomura MD, PhD, Ryosuke Takeshima MD, PhD, Azusa Hiura MD, PhD, Kotaro Hayashi MD, PhD, Atsuko Fukuyasu MD, PhD, Takamitsu Tanaka MD, PhD, Takeko Ishikawa MD, PhD, Yayoi Tada MD, PhD

引用次数: 0

Handheld digital microscope for dermatoscopy 用于皮肤检查的手持式数码显微镜

IF 5.2

JAAD International

Pub Date : 2025-11-28 DOI: 10.1016/j.jdin.2025.11.017

Chenan A. Huang MD , Anna K. Martino BS , Emily E. Antalika BA , Megan A. Bernier MD , Clara H. Ambrose , Sara M. Asbeck MD, MPH , Steven R. Feldman MD, PhD , Zeynep M. Akkurt MD

引用次数: 0

Hyaluronidase for microstomia in fibrosing skin disease: Systematic review and case series 透明质酸酶治疗纤维化皮肤病小口症：系统综述和病例系列

IF 5.2

JAAD International

Pub Date : 2025-11-28 DOI: 10.1016/j.jdin.2025.11.012

Catherine Zhu MD , Ghassan Barnawi MD , Elen Grigorchuk , Ethan Bendayan , Katya Peri MSc , François Lagacé MD , Houriah Y. Nukaly MD , Elena Netchiporouk MD, MSc

引用次数: 0

Rosacea prevalence, severity, and phenotype by race, ethnicity, and gender: A cross-sectional study of a diverse patient cohort within a primary care population 酒渣鼻的患病率、严重程度和表型与种族、民族和性别有关：一项对初级保健人群中不同患者队列的横断面研究

IF 5.2

JAAD International

Pub Date : 2025-11-27 DOI: 10.1016/j.jdin.2025.11.016

Alexander R. Gomez-Lara BA, BS , Adam Zakaria MD, MAS , Maria Elena Sanchez-Anguiano BS , Erin H. Amerson MD

引用次数: 0

Patient preferences in the benefit–risk assessment of atopic dermatitis treatments in China: A nationwide survey 中国特应性皮炎治疗获益-风险评估中的患者偏好：一项全国性调查

IF 5.2

JAAD International

Pub Date : 2025-11-27 DOI: 10.1016/j.jdin.2025.11.011

Jingyi Yang MS , Yang Liu MD , Hengjing Li PhD , Yumei Ge MD, PhD , Chen Yin PhD , Yun Zhai MD, PhD , Cong Zhao MS , Siyuan Qian MS , Xiaoyuan Chen PhD , Songmei Xie MD, PhD

Background

Understanding patient preferences is critical for patient-focused drug development, especially in chronic conditions like atopic dermatitis, where treatment benefit–risk profiles vary widely.

Objective

To evaluate treatment priorities, risk tolerance, and benefit–risk acceptance among Chinese patients with atopic dermatitis.

Methods

A nationwide, cross-sectional online survey was conducted between February and July 2023. Patients with physician-diagnosed atopic dermatitis or their caregivers were recruited via major dermatology hospitals and patient communities. The survey evaluated treatment goals, unacceptable adverse events, and willingness to accept risks under scenarios of near-complete versus partial recovery.

Results

Of 2120 respondents, 1948 valid responses were analyzed. Top treatment goals were reducing flare-ups (84%), preventing complications (61%), and relieving itch and pain (52%). Most unacceptable adverse events were serious infections (67%) and malignancies (65%). Patients showed increased risk tolerance when treatments promised near-complete recovery (15% fully accepted <0.1% risk of severe reactions) versus partial improvement (10%). Risk tolerance was lower among patients under 18 years and those with mild-to-moderate disease.

Limitations

Self-reported data and online recruitment may limit generalizability.

Conclusion

Chinese patients are more willing to accept treatment risks when greater benefits are expected. Preferences vary by age and severity, supporting more personalized treatment discussions and decisions.

背景：了解患者偏好对于以患者为中心的药物开发至关重要，特别是在像特应性皮炎这样的慢性疾病中，治疗收益-风险概况差异很大。目的评价中国特应性皮炎患者的治疗优先级、风险承受能力和获益-风险接受度。方法于2023年2月至7月在全国范围内进行横断面在线调查。医生诊断为特应性皮炎的患者或其护理人员通过主要皮肤科医院和患者社区招募。该调查评估了治疗目标、不可接受的不良事件以及在接近完全恢复和部分恢复的情况下接受风险的意愿。结果对2120名调查对象的有效问卷进行了1948次分析。主要治疗目标是减少发作（84%）、预防并发症（61%）和缓解瘙痒和疼痛（52%）。最不可接受的不良事件是严重感染（67%）和恶性肿瘤（65%）。与部分改善（10%）相比，当治疗承诺接近完全恢复（15%完全接受和0.1%严重反应风险）时，患者表现出更高的风险承受能力。18岁以下患者和轻中度疾病患者的风险承受能力较低。自我报告的数据和在线招聘可能会限制普遍性。结论在获益预期较大的情况下，中国患者更愿意接受治疗风险。偏好因年龄和严重程度而异，支持更个性化的治疗讨论和决定。

{"title":"Patient preferences in the benefit–risk assessment of atopic dermatitis treatments in China: A nationwide survey","authors":"Jingyi Yang MS , Yang Liu MD , Hengjing Li PhD , Yumei Ge MD, PhD , Chen Yin PhD , Yun Zhai MD, PhD , Cong Zhao MS , Siyuan Qian MS , Xiaoyuan Chen PhD , Songmei Xie MD, PhD","doi":"10.1016/j.jdin.2025.11.011","DOIUrl":"10.1016/j.jdin.2025.11.011","url":null,"abstract":"<div><h3>Background</h3><div>Understanding patient preferences is critical for patient-focused drug development, especially in chronic conditions like atopic dermatitis, where treatment benefit–risk profiles vary widely.</div></div><div><h3>Objective</h3><div>To evaluate treatment priorities, risk tolerance, and benefit–risk acceptance among Chinese patients with atopic dermatitis.</div></div><div><h3>Methods</h3><div>A nationwide, cross-sectional online survey was conducted between February and July 2023. Patients with physician-diagnosed atopic dermatitis or their caregivers were recruited via major dermatology hospitals and patient communities. The survey evaluated treatment goals, unacceptable adverse events, and willingness to accept risks under scenarios of near-complete versus partial recovery.</div></div><div><h3>Results</h3><div>Of 2120 respondents, 1948 valid responses were analyzed. Top treatment goals were reducing flare-ups (84%), preventing complications (61%), and relieving itch and pain (52%). Most unacceptable adverse events were serious infections (67%) and malignancies (65%). Patients showed increased risk tolerance when treatments promised near-complete recovery (15% fully accepted <0.1% risk of severe reactions) versus partial improvement (10%). Risk tolerance was lower among patients under 18 years and those with mild-to-moderate disease.</div></div><div><h3>Limitations</h3><div>Self-reported data and online recruitment may limit generalizability.</div></div><div><h3>Conclusion</h3><div>Chinese patients are more willing to accept treatment risks when greater benefits are expected. Preferences vary by age and severity, supporting more personalized treatment discussions and decisions.</div></div>","PeriodicalId":34410,"journal":{"name":"JAAD International","volume":"24 ","pages":"Pages 306-314"},"PeriodicalIF":5.2,"publicationDate":"2025-11-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145924383","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

In vivo molecular skin fluorescence imaging for noninvasive assessment of atypical nevi and melanoma: A validation trial 活体分子皮肤荧光成像非典型痣和黑色素瘤的无创评估：一项验证试验

IF 5.2

JAAD International

Pub Date : 2025-11-26 DOI: 10.1016/j.jdin.2025.11.010

Douglas Grossman MD, PhD , Elizabeth Berry MD , Justin M. Ko MD , Raja Sivamani MD , Serena Mraz MD , Sunil S. Dhawan MD , Kevin Manbeck MS , Amit Shachaf PhD , Shamika Majmudar MS , Catherine Shachaf PhD , Sancy Leachman MD, PhD

Background

Current visual assessments and assistive technologies for melanoma detection primarily focus on detecting morphological changes, often requiring invasive biopsies for confirmation.

Objective

To determine the efficacy of skin fluorescent imaging (SFI), a novel noninvasive technology for detection of αvβ3 integrin in the tumor microenvironment, for discrimination of benign from malignant melanocytic lesions.

Methods

A prospective validation trial evaluated 240 clinically suspicious cutaneous pigmented lesions prior to biopsy in 6 academic and community dermatology clinics in California, Utah, and Oregon.

Results

The distribution of lesions included 99 (41%) lesions without dysplasia, 59 (25%) nevi with low-grade dysplasia, 51 (21%) nevi with high-grade dysplasia, 20 (8.3%) melanoma in situ, and 11 invasive melanomas (4.6%). SFI cutoff scores of 5 and 7 demonstrated sensitivities of 93% and 87% and specificities of 77% and 91%, respectively, for discrimination of lesions with no or low-grade dysplasia from those with high-grade dysplasia or melanomas. The area under the receiver operating characteristic curve was 0.907 (95% CI 0.864-0.951, P <.0001).

Limitations

This was a single-arm trial.

Conclusions

SFI demonstrated high sensitivity and specificity for discriminating low-risk from high-risk lesions, representing a promising approach to enhance evaluation of clinically concerning pigmented lesions and reduce unnecessary biopsies.

目前黑色素瘤检测的视觉评估和辅助技术主要集中在检测形态学变化，通常需要侵入性活检来确认。目的探讨一种新型的无创检测肿瘤微环境中αvβ3整合素的方法——皮肤荧光成像（SFI）在黑色素细胞病变良恶性鉴别中的应用价值。方法一项前瞻性验证试验评估了加利福尼亚州、犹他州和俄勒冈州6个学术和社区皮肤科诊所的240例临床可疑皮肤色素病变。结果无发育不良99例（41%），低级别发育不良59例（25%），高级别发育不良51例（21%），原位黑色素瘤20例（8.3%），浸润性黑色素瘤11例（4.6%）。SFI临界值为5分和7分，在区分无或低级别非典型增生病变与高级别非典型增生或黑色素瘤时，其敏感性分别为93%和87%，特异性分别为77%和91%。受试者工作特征曲线下面积为0.907 （95% CI 0.864-0.951, P < 0.0001）。局限性：这是一项单臂试验。结论ssfi在区分低风险和高风险病变方面具有较高的敏感性和特异性，是一种很有前景的方法，可以加强临床对色素病变的评估，减少不必要的活检。

{"title":"In vivo molecular skin fluorescence imaging for noninvasive assessment of atypical nevi and melanoma: A validation trial","authors":"Douglas Grossman MD, PhD , Elizabeth Berry MD , Justin M. Ko MD , Raja Sivamani MD , Serena Mraz MD , Sunil S. Dhawan MD , Kevin Manbeck MS , Amit Shachaf PhD , Shamika Majmudar MS , Catherine Shachaf PhD , Sancy Leachman MD, PhD","doi":"10.1016/j.jdin.2025.11.010","DOIUrl":"10.1016/j.jdin.2025.11.010","url":null,"abstract":"<div><h3>Background</h3><div>Current visual assessments and assistive technologies for melanoma detection primarily focus on detecting morphological changes, often requiring invasive biopsies for confirmation.</div></div><div><h3>Objective</h3><div>To determine the efficacy of skin fluorescent imaging (SFI), a novel noninvasive technology for detection of αvβ3 integrin in the tumor microenvironment, for discrimination of benign from malignant melanocytic lesions.</div></div><div><h3>Methods</h3><div>A prospective validation trial evaluated 240 clinically suspicious cutaneous pigmented lesions prior to biopsy in 6 academic and community dermatology clinics in California, Utah, and Oregon.</div></div><div><h3>Results</h3><div>The distribution of lesions included 99 (41%) lesions without dysplasia, 59 (25%) nevi with low-grade dysplasia, 51 (21%) nevi with high-grade dysplasia, 20 (8.3%) melanoma in situ, and 11 invasive melanomas (4.6%). SFI cutoff scores of 5 and 7 demonstrated sensitivities of 93% and 87% and specificities of 77% and 91%, respectively, for discrimination of lesions with no or low-grade dysplasia from those with high-grade dysplasia or melanomas. The area under the receiver operating characteristic curve was 0.907 (95% CI 0.864-0.951, <em>P</em> <.0001).</div></div><div><h3>Limitations</h3><div>This was a single-arm trial.</div></div><div><h3>Conclusions</h3><div>SFI demonstrated high sensitivity and specificity for discriminating low-risk from high-risk lesions, representing a promising approach to enhance evaluation of clinically concerning pigmented lesions and reduce unnecessary biopsies.</div></div>","PeriodicalId":34410,"journal":{"name":"JAAD International","volume":"24 ","pages":"Pages 279-286"},"PeriodicalIF":5.2,"publicationDate":"2025-11-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145883300","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Soft tissue atrophy following intralesional corticosteroid injection for infantile hemangioma: A retrospective cohort study 儿童血管瘤瘤内皮质类固醇注射后软组织萎缩：一项回顾性队列研究

IF 5.2

JAAD International

Pub Date : 2025-11-25 DOI: 10.1016/j.jdin.2025.11.003

Jie Jiang MBBS, Rui Chang MM, Jingjing Sun MBBS, Shih-Jen Chang MD, PhD, Lei Chang PhD, Xiaoxi Lin PhD, Yajing Qiu MD

引用次数: 0

Predicting outcomes of port-wine stains treated with hematoporphyrin monomethyl ether photodynamic therapy (HMME-PDT): An observational study using multimodal deep learning 血卟啉单甲基醚光动力疗法（HMME-PDT）治疗波特酒斑的预后预测：一项使用多模态深度学习的观察性研究

IF 5.2

JAAD International

Pub Date : 2025-11-21 DOI: 10.1016/j.jdin.2025.11.009

Jinjin Zhu MD , Chunhui Xie PhD , Yan Li MD , Xue Wang MD , Ziqiong Cheng MD , Yunqi Li PhD , Juan Tao MD, PhD

引用次数: 0

Histopathologic features of nutritional deficiency dermatoses: A two-center series 营养缺乏性皮肤病的组织病理学特征：双中心系列

IF 5.2

JAAD International

Pub Date : 2025-11-20 DOI: 10.1016/j.jdin.2025.10.018

Silvija Milanovic BS , Emily Draper BA , Milbrey Parke MD , Catherine G. Chung MD , Abena Minta MD , Kiran Motaparthi MD

引用次数: 0

首页上一页

下一页尾页

类型

全部化学•材料生命科学医学物理工程技术环境•农林材料科学地球科学法学管理学化学环境科学与生态学计算机科学教育学经济学农林科学人文科学生物学数学物理与天体物理心理学综合性期刊其他工业工程理学历史学农学文学信息工程

数据库

全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley

期刊

JAAD International

全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.

﹀